107 related articles for article (PubMed ID: 21428212)
1. Human sodium iodide symporter (hNIS) in fibroadenoma breast--a immunohistochemical study.
Rai R; Shrivastava A; Tandon A; Godbole MM; Kumar S; Das V; Dwivedi V; Pal L
Indian J Exp Biol; 2011 Feb; 49(2):113-7. PubMed ID: 21428212
[TBL] [Abstract][Full Text] [Related]
2. Sodium iodide symporter, estrogen receptor, and progesterone receptor expression in carcinoma breast--an immunohistochemical analysis.
Tandon A; Shrivastava A; Kumar A; Prayaga AK; Sundaram C; Godbole MM
Indian J Pathol Microbiol; 2011; 54(4):745-51. PubMed ID: 22234102
[TBL] [Abstract][Full Text] [Related]
3. Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma.
Berger F; Unterholzner S; Diebold J; Knesewitsch P; Hahn K; Spitzweg C
Biochem Biophys Res Commun; 2006 Nov; 349(4):1258-63. PubMed ID: 16982034
[TBL] [Abstract][Full Text] [Related]
4. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands.
Spitzweg C; Joba W; Schriever K; Goellner JR; Morris JC; Heufelder AE
J Clin Endocrinol Metab; 1999 Nov; 84(11):4178-84. PubMed ID: 10566669
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus.
Lee WW; Lee B; Kim SJ; Jin J; Moon DH; Lee H
Oncol Rep; 2003; 10(4):845-9. PubMed ID: 12792733
[TBL] [Abstract][Full Text] [Related]
6. Expression of sodium iodide symporter in benign and malignant human thyroid tissues.
Lin JD; Hsueh C; Chao TC; Weng HF
Endocr Pathol; 2001; 12(1):15-21. PubMed ID: 11478264
[TBL] [Abstract][Full Text] [Related]
7. Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Li BX; Li J; Luo CL; Zhang MC; Li H; Li LL; Xu HF; Shen YW; Xue AM; Zhao ZQ
Indian J Exp Biol; 2013 Mar; 51(3):208-17. PubMed ID: 23678541
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
10. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Romijn JA; van der Heide D
Exp Clin Endocrinol Diabetes; 2001; 109(1):52-5. PubMed ID: 11573141
[TBL] [Abstract][Full Text] [Related]
11. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders.
Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG
Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657
[TBL] [Abstract][Full Text] [Related]
12. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
13. O-glycosylation expression in fibroadenoma.
Gallegos B; Pérez-Campos E; Martinez R; Leyva P; Martinez M; Hernández R; Pina S; Hernández C; Zenteno E; Hernández P
Prep Biochem Biotechnol; 2010; 40(1):1-12. PubMed ID: 20024790
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
Haberkorn U
Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions.
Farnedi A; Eusebi LH; Poli F; Foschini MP
Int J Surg Pathol; 2009 Aug; 17(4):327-34. PubMed ID: 19124451
[TBL] [Abstract][Full Text] [Related]
16. Quantitative immunohistochemical analysis reveals association between sodium iodide symporter and estrogen receptor expression in breast cancer.
Chatterjee S; Malhotra R; Varghese F; Bukhari AB; Patil A; Budrukkar A; Parmar V; Gupta S; De A
PLoS One; 2013; 8(1):e54055. PubMed ID: 23342072
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues.
Jhiang SM; Cho JY; Ryu KY; DeYoung BR; Smanik PA; McGaughy VR; Fischer AH; Mazzaferri EL
Endocrinology; 1998 Oct; 139(10):4416-9. PubMed ID: 9751526
[TBL] [Abstract][Full Text] [Related]
18. Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer.
Kilbane MT; Ajjan RA; Weetman AP; Dwyer R; McDermott EW; O'Higgins NJ; Smyth PP
J Clin Endocrinol Metab; 2000 Mar; 85(3):1245-50. PubMed ID: 10720070
[TBL] [Abstract][Full Text] [Related]
19. P53 expression in patients with malignant and benign breast diseases.
Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS
Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110
[TBL] [Abstract][Full Text] [Related]
20. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
